HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/24003

Title:	HER2 Testing and Clinical Decision Making in Gastroesophageal Adenocarcinoma: Guideline From the College of American Pathologists, American Society for Clinical Pathology, and American Society of Clinical Oncology.
Authors:	Bartley, Angela N Washington, Mary Kay Ventura, Christina B Ismaila, Nofisat Colasacco, Carol Benson, Al B Carrato, Alfredo Gulley, Margaret L Jain, Dhanpat Kakar, Sanjay Mackay, Helen J Streutker, Catherine Tang, Laura Troxell, Megan Ajani, Jaffer A View more
Keywords:	Gastroesophageal adenocarcinoma Guidelines HER2 testing View more
Mesh:	Adenocarcinoma Antineoplastic Agents Esophageal Neoplasms Esophagogastric Junction Genetic Testing Humans Medical Oncology Receptor, ErbB-2 Stomach Neoplasms United States Clinical Decision-Making View more
Issue Date:	Dec-2016
Citation:	Am. J. Clin. Pathol..2016 Dec;(146)6:647-669
Abstract:	ERBB2 (erb-b2 receptor tyrosine kinase 2 or HER2) is currently the only biomarker established for selection of a specific therapy for patients with advanced gastroesophageal adenocarcinoma (GEA). However, there are no comprehensive guidelines for the assessment of HER2 in patients with GEA.
PMID:	28077399
URI:	https://hdl.handle.net/20.500.12530/24003
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC6272805.pdf		1.46 MB	Adobe PDF	View/Open